Even though Breast Cancer Campaign receive funding from Roche they place the blame pretty squarely on Roche for unrealistic pricing.

Of course NICE rejected this medication - one of the functions of NICE is to drive costs of medication down. There was, and still is, a problem where drug companies make drugs that offer a few months of extra life and who then fund patient activist groups to advocate for those drugs to be prescribed. (This drug provides a bit less than six months of extra life so it's pretty good. Other drugs were about as expensive and it wasn't clear whether they offered a week or so extra life, or none.)

The drug is still available through the cancer drugs fund. And even if the price dropped to a point that NICE would recommend it it would still be so expensive that it would be available through specialist commissioning.

http://donate.breastcancercampaign.org/document.doc?id=82